Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
HIV Infections
Interventions
BIOLOGICAL

AVX101

Alphavirus replicon particle vaccine expressing HIV Gag antigen

OTHER

placebo

phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose

Trial Locations (8)

2013

Perinatal HIV Research Unit, Chris Hani Baragwanat, Bertsham

10003

New York Blood Center - Union Square, New York

10032

Columbia University, New York

10456

New York Blood Center - Bronx, The Bronx

37232

Vanderbilt University, Nashville

21205-1901

Johns Hopkins University, Baltimore

14642-0001

University of Rochester, Rochester

Unknown

Botswana HIV Vaccine Clinical Eval. Ctr, Princess, Gaborone

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

AlphaVax, Inc.

INDUSTRY